<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905759</url>
  </required_header>
  <id_info>
    <org_study_id>FMBSURECS/31032019/Mohammed</org_study_id>
    <nct_id>NCT03905759</nct_id>
  </id_info>
  <brief_title>Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG</brief_title>
  <official_title>Preoperative Colchicine, Dronedarone Or Amiodarone for Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG; A Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>doaa rashwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation in the postoperative period of myocardial revascularization surgery&#xD;
      (AF-POMR) occurs in 10% to 65% of patients, increasing morbidity and mortality after surgery.&#xD;
      is associated with an increase in hospital length of stay, and, thus, in costs,and can cause&#xD;
      serious clinical complications, such as hypotension, heart failure, stroke and other&#xD;
      thromboembolic disorders.Although not completely understood, the electrophysiological&#xD;
      mechanism of AF-POMR is believed to be reentry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study The aim of this work is to study the effect of preoperative Colchicine,&#xD;
      Dronedarone or Amiodarone for prophylaxis against postoperative atrial fibrillation in&#xD;
      patients undergoing on-pump CABG.&#xD;
&#xD;
      Patients and Methods&#xD;
&#xD;
      Type and site of the study:&#xD;
&#xD;
      This randomized double blinded clinical study will be carried out at Beni-Suef university&#xD;
      hospital, after approval by the department of Anesthesiology, Pain management and Surgical&#xD;
      ICU, the local ethics and research committee and other involved departments, faculty of&#xD;
      medicine, Beni-Suef University.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      The study population will include inpatients of the cardiothoracic department scheduled for&#xD;
      CABG surgery, both sex, selected randomly according to American Society of&#xD;
      Anesthesiologists(ASA) grade II and III, between the ages of 40 -60ears.&#xD;
&#xD;
      Exclusion criteria:.&#xD;
&#xD;
        -  Liver dysfunction, pregnancy.&#xD;
&#xD;
        -  History of allergic reaction to any drug used in this study.&#xD;
&#xD;
        -  Emergency procedure&#xD;
&#xD;
        -  Preoperative dialysis&#xD;
&#xD;
        -  A.F.&#xD;
&#xD;
        -  Patients on antiarrhythmic medications&#xD;
&#xD;
      Sample size estimation:&#xD;
&#xD;
      As considered the primary outcome, sample size calculation was done using the comparison of&#xD;
      the rate of occurrence of postoperative AF in cases undergoing on-pump CABG pretreated with&#xD;
      colchicine, dronedarone or amiodarone. As previously published 19 , the rate of postoperative&#xD;
      AF among amiodarone group was 25%, while in colchicine, it was 7% 20. investigators assumed&#xD;
      that dronedarone treatment will differ about 20% from amiodarone and selected the least&#xD;
      excepted difference to do the calculation. Therefore, the calculation was done based on&#xD;
      comparing 2 proportions from independent samples using Chi test, the α-error level was fixed&#xD;
      at 0.05 and the power was set at 80%.&#xD;
&#xD;
      Accordingly, the optimum sample size should be 48 cases in each arm. Sample size calculation&#xD;
      was done using PS Power and Sample Size Calculations software, version 3.0.11 for MS Windows&#xD;
      (William D. Dupont and Walton D. Vanderbilt, USA).&#xD;
&#xD;
      Sampling Technique:&#xD;
&#xD;
      The patients will be randomly divided into three groups, as follows: Group c: Colchicine will&#xD;
      be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg,&#xD;
      twice daily, until hospital discharge ; Group D: Dronedarone (200 mg twice daily starting&#xD;
      from day before operation till 5 days after) ; Group A:-amiodarone (200 mg three times per&#xD;
      day)21 administered 6 days prior to surgery through 6 days after surgery Randomization&#xD;
      assignment of patients to Groups C, D and A will be performed with a list of random numbers&#xD;
      generated by a computer program's random function. The allocation into the groups and the&#xD;
      preparation of the study drug will be performed by an individual who as unrelated to the&#xD;
      study. Personnel, patients, and the individual participating in the data collection and data&#xD;
      analysis will be blinded to the treatment assignments.&#xD;
&#xD;
      Anesthesia Management The patients will be evaluated preoperatively 1 day before surgery.&#xD;
      Electrocardiogram (ECG), pulse oximetry, cannulation of the invasive arterial pressure (20&#xD;
      gauge) from the left radial artery, and peripheral venous access (18 gauge) from the right&#xD;
      arm will be inserted into the patient, who will be taken to the operating room on the day of&#xD;
      the surgery. After induction of anesthesia and intubation, an 8F central venous catheter will&#xD;
      be inserted from the right internal jugular vein. Midazolam (0.05 mg/kg), propofol (2 mg/kg),&#xD;
      fentanyl (5 mcg/kg), and rocuronium (0.6 mg/kg) will be used for the induction of anesthesia.&#xD;
      Anesthesia will be maintained with a mixture of 2% sevoflurane, 60% oxygen, and 40% air.&#xD;
&#xD;
      All patients will be ventilated with positive pressure. Ventilation parameters will be set as&#xD;
      a tidal volume of 8ml/kg and a respiratory rate of 10-12/min, which will be assessed by&#xD;
      arterial blood gases. All patients will receive 500 ml ringer lactat before the induction of&#xD;
      anesthesia. Thereafter, IV ringer lactate solution will be infused to keep the central venous&#xD;
      pressure (CVP) at 10-12 mmHg.&#xD;
&#xD;
      Cardiopulmonary Bypass Management Before cannulation for CPB, 3 mg/kg of heparin will be&#xD;
      administered for all patients. When the activated coagulation time will be &gt; 400/sec, it will&#xD;
      be passed to the pump.&#xD;
&#xD;
      Nonpulsatile CPB flow rates of 2-2.4 L/min/m2 will be applied, and the mean arterial pressure&#xD;
      (MAP) will be kept at 50-60 mmHg. Hematocrit concentration will be maintained at 25-28%.&#xD;
      Moreover, mild hypothermia (28-30°C) will be reached during CPB. Myocardial protection will&#xD;
      be achieved with intermittent antegradecardtemperature of 37°C will be achieved after&#xD;
      surgery, and the patient will be removed from CPB. Following this, coagulation will be&#xD;
      provided with protamine; once hemodynamic stabilization (MAP 70-90 mmHg) will be achieved,&#xD;
      patients will be brought to the intensive care unit.&#xD;
&#xD;
      Data Collection Methods:&#xD;
&#xD;
      The following parameters will be evaluated and recorded by senior anesthesiologist unaware of&#xD;
      the study protocol:&#xD;
&#xD;
        -  Demographic data (age, sex, and weight)&#xD;
&#xD;
        -  Perioperative data (operation time, cross-clamp time, EF ).&#xD;
&#xD;
        -  Post bypass and post operative AF&#xD;
&#xD;
        -  Hospital stay and death&#xD;
&#xD;
      Statistical analysis Continuous variables will be summarized as mean ± SD and categorical&#xD;
      variables Will be expressed as proportion (%). Univariate analyses will be performed by&#xD;
      chi-square, student's t-test, Fisher exact test, Mann Whitney test and One-way ANOVA (will be&#xD;
      used for comparison between the three groups). SPSS for Windows (version 17; SPSS Inc.,&#xD;
      Chicago, IL., USA) will be used for statistical analysis. Results will be considered&#xD;
      significant if P values are less than 0.05p&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">April 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF</measure>
    <time_frame>change from baseline rhythm at 6 days</time_frame>
    <description>incidence of AF</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Postoperative Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronedarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dronedarone (200 mg twice daily starting from day before operation till 5 days after)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronedarone</intervention_name>
    <description>Dronedarone (200 mg twice daily starting from day before operation till 5 days after)</description>
    <arm_group_label>Dronedarone</arm_group_label>
    <other_name>amiodarone,colchicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery</description>
    <arm_group_label>amiodarone</arm_group_label>
    <other_name>colchicine ,dronedarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge</description>
    <arm_group_label>colchicine</arm_group_label>
    <other_name>amiodarone, dorendarone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The study population will include inpatients of the cardiothoracic department scheduled for&#xD;
        CABG surgery, both sex, selected randomly according to American Society of&#xD;
        Anesthesiologists(ASA) grade II and III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Liver dysfunction, pregnancy.&#xD;
&#xD;
          -  History of allergic reaction to any drug used in this study.&#xD;
&#xD;
          -  Emergency procedure&#xD;
&#xD;
          -  Preoperative dialysis&#xD;
&#xD;
          -  A.F.&#xD;
&#xD;
          -  Patients on antiarrhythmic medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>belal Y Mohammed, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine Beni-Suef University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doaa A Rashwan, MD</last_name>
    <phone>00201011270763</phone>
    <email>doaa_rashwan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Belal Y Mohammed, Msc</last_name>
    <phone>0020124138153</phone>
    <email>byahia37@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty Of Medicine, Beni-Suef University</name>
      <address>
        <city>Banī Suwayf</city>
        <zip>11391</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>doaa rashwan, md</last_name>
      <phone>00201011270763</phone>
      <email>doaa_rashwan@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>doaa rashwan</investigator_full_name>
    <investigator_title>Assistant profesor Doaa Rashwan</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Dronedarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>the protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>after registration for ever</ipd_time_frame>
    <ipd_access_criteria>on the web page</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

